Trial Profile
THE ROLE OF HYPERGLYCEMIA, HYPERINSULINEMIA AND ELEVATED FREE FATTY ACIDS FOR CARDIAC FUNCTION IN PATIENTS WITH TYPE 2 DIABETES – THE HYPERCARD2 STUDY
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2022
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Insulin suspension isophane
- Indications Cardiovascular disorders
- Focus Therapeutic Use
- Acronyms HyperCarD2
- 23 Sep 2022 Primary endpoint has not been met (Myocardial diastolic function (Cardiac MRI), as per Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes
- 23 Sep 2022 Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
- 23 Sep 2022 Results assessing the effects of empagliflozin on BGS first, and peripheral insulin sensitiv-ity (IS) second, compared to simi lar glycemic control with insulintreatment, presented at the 58th Annual Meeting of the European Association for the Study of Diabetes..